Abstract：Objective To study the therapeutic effects of different doses of botulinum toxin A (BTX-A) injection on tiptoe deformation in children with cerebral palsy. Methods A total of 256 children with tiptoe deformation due to spastic cerebral palsy were classified into group A (muscle tension levels I-II, n=147) and group B (muscle tension levels III-IV, n=109). Group A was randomly divided into group A1 (injected with high-dose BTX-A, n=73) and group A2 (injected with low-dose BTX-A, n=74). Group B was randomly divided into group B1 (injected with high-dose BTX-A, n=55) and group B2 (injected with low-dose BTX-A, n=54). The dose of BTX-A was 6 U/kg for groups A1 and B1 and was 3 U/kg for groups A2 and B2. Before the injection and at 1,2,6, and 12 months after injection, the muscle tension of limbs was evaluated with the modified Ashworth Scale, and the recovery of motor function of lower limbs was assessed with the Gross Motor Function Measure (GMFM). Results Before and after treatment, there were no significant differences in Ashworth and GMFM scores between groups A1 and A2 (P>0.05). After treatment, group B1 had a significantly reduced Ashworth score and a significantly increased GMFM score, and group B1 had a significantly lower Ashworth score and a significantly higher GMFM score compared with group B2 (PPConclusions The level of muscle tension should be considered when BTX-A injection is used for treating tiptoe deformation in children with cerebral palsy. It makes no difference to use high-or low-dose BTX-A when the muscle tension level is within I-II, but high-dose BTX-A has a better performance in reducing muscle tension and improving motor function when the muscle tension level is within III-IV.
NIU Guo-Hui,ZHANG Xiao-Li,ZHU Deng-Na et al. Therapeutic effects of different doses of botulinum toxin A injection on tiptoe deformation in children with cerebral palsy[J]. CJCP, 2014, 16(7): 720-724.
Heinen F, Desloovere K, Schroeder AS, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy[J]. Eur J Paediatr Neurol, 2010, 14(1): 45-66.
[3]
Edgar TS. Clinical utility of botulinum toxin in the treatment of cerebral palsy: comprehensive review[J]. J Child Neurol, 2001, 16(1): 37-46.
[4]
Camargo CH, Teive HA, Zonta M, et al. Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy[J]. Arq Neuropsiquiatr, 2009, 67(1): 62-68.
[5]
Py AG, Zein Addeen G, Perrier Y, et al. Evaluation of the effectiveness of botulinum toxin injections in the lower limb muscles of children with cerebral palsy. Preliminary prospective study of the advantages of ultrasound guidance[J]. Ann Phys Rehabil Med, 2009, 52(3): 215-223.
[6]
Kinnett D. Botulinum toxin A injections in children: technique and dosing issues[J]. Am J Phys Med Rehabil, 2004, 83(10): S59-S64.
Aoki KR. Harmacology and immunology of botulinumtoxin type A[J]. Clin Dermatol, 2003, 21(6): 476-480.
[12]
Polak F, Morton R, Ward C, et al. Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy[J]. Dev Med Child Neurol, 2002, 44(8): 551-555.
[13]
Baker R, Jasinski M, Maciag-Tymecka I, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study[J]. Dev Med Child Neurol, 2002, 44(10): 666-675.
